RELMADA THERAPEUTICS, INC. (RLMD) Form 10-Q — May 12, 2026
Relmada Therapeutics, Inc. reported a net loss of $19,051,956 for the three months ended March 31, 2026, with a loss per share of $0.22. The company's cash and cash equivalents as of March 31, 2026, were $9,776,400, up from $3,496,540 as of December 31, 2025. The company completed a private placement on March 11, 2026, raising approximately $150 million in net proceeds.
Key figures
- Eps
- -0.22
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -19,051,956
- Total Debt
- 16,630,217
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 235,362,794
- Cash Position
- 9,776,400
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 150,000,000
- Offering Price
- 4.75
- Shares Offered
- 29,474,569
- Shares Outstanding
- 104,890,223
- Short Term Investments
- 224,186,743
- Net Cash Flow From Financing
- 156,574,345
- Net Cash Flow From Investing
- -135,226,997
- Net Cash Flow From Operating
- -15,067,488
Price after filing
1 day: +0.5%7 days: -5.6%30 days: -14.4%
Close on the filing date to close N calendar days later (from $7.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.